Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome
| Autor: | Ripoll, VM, Pregnolato, F, Mazza, S, Bodio, C, Grossi, C, McDonnell, T, Pericleous, C, Meroni, PL, Isenberg, DA, Rahman, A, Giles, IP |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
GROWTH-FACTOR
Science & Technology PROTEINS Immunology Gene expression profiling Monocytes TROPHOBLAST INVASION RECURRENT MISCARRIAGE ACTIVATION PATHWAY PREGNANCY MONOCYTES 1107 Immunology ANTIBODIES Vascular thrombosis Pregnancy morbidity SYSTEMIC-LUPUS-ERYTHEMATOSUS Life Sciences & Biomedicine APS |
| Popis: | Antiphospholipid antibodies (aPL) cause vascular thrombosis (VT) and/or pregnancy morbidity (PM). Differential mechanisms however, underlying the pathogenesis of these different manifestations of antiphospholipid syndrome (APS) are not fully understood. Therefore, we compared the effects of aPL from patients with thrombotic or obstetric APS on monocytes to identify different molecular pathways involved in the pathogenesis of APS subtypes. VT or PM IgG induced similar numbers of differentially expressed (DE) genes in monocytes. However, gene ontology (GO) analysis of DE genes revealed disease-specific genome signatures. Compared to PM, VT-IgG showed specific up regulation of genes associated with cell response to stress, regulation of MAPK signalling pathway and cell communication. In contrast, PM-IgG regulated genes involved in cell adhesion, extracellular matrix and embryonic and skeletal development. A novel gene expression analysis based on differential variability (DV) was also applied. This analysis identified similar GO categories compared to DE analysis but also uncovered novel pathways modulated solely by PM or VT-IgG. Gene expression analysis distinguished a differential effect of VT or PM-IgG upon monocytes supporting the hypothesis that they trigger distinctive physiological mechanisms. This finding contributes to our understanding of the pathology of APS and may lead to the development of different targeted therapies for VT or PM APS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|